Regulation of the Glucose Transport Pathway in Adipose Tissue of Horses with Insulin Resistance by Kohler, Kaleb
 1 
 
 
 
 
 
 
 
REGULATION OF THE GLUCOSE TRANSPORT PATHWAY IN 
ADIPOSE TISSUE OF HORSES WITH INSULIN RESISTANCE 
 
 
 
 
 
Undergraduate Thesis as Required for Graduation with Distinction 
 
 
 
 
 
 
Kaleb Kohler 
May 23, 2011 
 
Research Advisor: 
Dr. Veronique Lacombe 
 
Academic Advisor: 
Dr. Pasha Lyvers-Peffer 
 
Honors Research Project 
 2 
List of Figures and Tables 
 
 
Figure                 Figure Title      Page Number 
 
 
1   Total GLUT-4 and -12 Content of Insulin-Sensitive Horses  13 
 
 
2 A  GLUT-4 Protein Content in Insulin-Resistant Horses  15 
 
 
2 B  GLUT-12 Protein Content in Insulin-Resistant Horses  15 
 
 
3  Active Cell-Surface GLUT-4 Comparison    17 
 
 
4  Active Cell-Surface GLUT-12 Comparison    18 
 
 
5 A  Total AS160 Protein Content Comparison    20 
 
 
5 B  Phosphorylated AS160 Protein Content Comparison  20 
 
 
 
Table                 Table Title      Page Number 
 
1  Baseline Physical and Physiological Comparison   11  
 
 3 
 
Common Abbreviations 
GLUT: Glucose Transporter 
AS160: Akt Substrate 160  
IS: Insulin sensitive 
IR: Insulin resistant 
SM: Skeletal Muscle 
AT: Adipose Tissue 
TH: Tailhead (adipose tissue) 
NL: Nuchal ligament (adipose tissue) 
MES: Mesenteric (adipose tissue) 
RP: Retroperitoneal (adipose tissue) 
OM: Omental (adipose tissue) 
SC: Subcutaneous (adipose tissue) 
VIS: Visceral (adipose tissue) 
CASQ: Calsequestrin 
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ABSTRACT: 
Although the importance of adipose tissue (AT) glucose transport in regulating systemic insulin 
sensitivity is becoming increasingly evident and insulin resistance (IR) has been widely 
recognized, the underlying alterations in glucose transport and its contributions to IR are still not 
well understood. The purpose of the present study was to determine the early pathological 
changes in glucose transport by characterizing alterations in glucose transporters (GLUTs) in 
visceral and subcutaneous adipose depots in a novel equine model of naturally occurring 
compensated IR. AT biopsies were collected from horses, which were classified as insulin-
sensitive (IS) or compensated IR based on the results of an insulin-modified frequently sampled 
intravenous glucose tolerance test. Protein expression of GLUT-4 (major isoform) and GLUT-12 
(a newly discovered isoform) were measured by Western blotting in visceral and subcutaneous 
adipose depots, along with AS160 (a potential key protein in GLUT cell-surface trafficking). 
Using a biotinylated bis-mannose photolabel technique, active cell surface GLUT-4 and-12 
content was also quantified to estimate GLUT trafficking. Omental AT had the highest total 
GLUT-4 and GLUT-12 content compared to other sites during the IS state. IR was associated 
with a significantly reduced total GLUT-4, but not GLUT-12, content in omental AT, without a 
change in content in the other adipose sites. In addition, active cell surface GLUT-4, but not -12, 
was lower in subcutaneous and visceral AT of IR compared to IS horses. Impairment in GLUT-4 
trafficking occurred independently of any changes in AS160 phosphorlyation between groups. 
The data suggests that GLUT-4, but not -12, is a pathogenic factor in AT during naturally 
occurring compensated IR, despite normal AS160 activation. 
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BACKGROUND:  
Diabetes mellitus has been known in humans since the early 20th century, and currently, 
approximately 171 million people worldwide (2.8% of the global population) are afflicted with 
the disease8.  By the year 2030, that number is expected to more than double, leading the Centers 
for Disease Control to label the disease as an epidemy11.  In particular, the vast majority of 
diabetes mellitus cases are Type II Diabetes mellitus (T2DM) 9.  T2DM is characterized by a lack 
of insulin action (i.e., insulin resistance), which causes hyperglycemia due to decreased glucose 
uptake into insulin-sensitive cells (i.e., muscle and adipose tissue), which if left untreated, can 
lead to multi-system organ dysfunction and potentially failure.  In more recent years, insulin 
resistance and obesity (both characteristic of T2DM) have been linked with hypertension and 
dyslipidemia in a disease phenotype known as metabolic syndrome, which is a generalized 
collection of risk factors for cardiovascular disease in humans1.  Additionally, there has been an 
increase in clinical awareness of insulin resistance and diabetes in horses, which has been rarely 
diagnosed or tested for in the past3.  While it is known that Type II diabetes results from insulin 
resistance, the exact mechanism and pathways by which glucose uptake into cells is decreased is 
not.  It has been known for the last 50 years that glucose uptake is mediated by a family of 
glucose transporters (GLUTs). GLUT4 is the major isoform and its translocation to the cell 
surface is mediated by both an insulin- and a contraction-regulated pathway2.  As such, we 
quantified the amount of the primary glucose transporter, GLUT-4, in adipose tissue in both 
insulin-sensitive and insulin-resistant horses.  Additionally, in an attempt to further investigate 
the mechanisms associated with decreased glucose uptake, the translocation of GLUT-4 from an 
intracellular pool (inactive site) to the cell surface (active site), the rate-limiting step for glucose 
uptake, was also studied.  Also, GLUT-12, a newly discovered GLUT protein, may present as a 
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second insulin-sensitive GLUT; however, its functional role is not well defined in insulin-
sensitive tissues, especially adipose tissue6.  With this in mind, total GLUT-12 content and 
activation were also quantified in the insulin-sensitive and insulin-resistant horses.  Leading 
research in related fields has also shown that there is a link between visceral adipose sites and the 
development of insulin resistance and cardiovascular disease in humans5.  Studies have shown 
that human omental adipocytes have higher glucose uptake rates than subcutaneous sites, 
resulting in more glucose transporter expression, and that visceral sites are more susceptible to 
glucocorticoid-induced insulin resistance than subcutaneous sites5.  We investigated this 
potential pathophysiologic process in our equine model by quantifying total and active amounts 
of glucose transporters in subcutaneous adipose tissues compared to visceral adipose tissues.  
Finally, the Akt Substrate Protein with a molecular weight of 160 kDa (AS 160) has recently 
been identified as a key player in both the insulin- and contraction-regulated pathways of glucose 
transporters.  AS160 is the most distally known signaling protein involved in GLUT-4 
translocation.  As such, the activity (or rather the lack thereof) of AS160 could be a potentially 
pathogenic factor for the development of insulin resistance and eventually diabetes.  
 
MATERIALS & METHODS: 
 
IN VIVO: 
The effect of insulin resistance on the regulation of glucose transport in adipose tissue was 
examined in an integrative physiologic study, using horses with naturally occurring insulin 
resistance.  In collaboration with the Ohio State University College of Veterinary Medicine, five 
insulin-resistant and five insulin-sensitive (control) light breed mares, housed at Finley Research 
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Farm, were sampled from the research herd and used for this study.  The horses were classified 
as either insulin-resistant or insulin-sensitive based on the results of an insulin-modified 
frequently sampled intravenous glucose tolerance test.  Horses chosen for inclusion in the study 
underwent general anesthesia at the Ohio State University Veterinary Teaching Hospital for 
incisional biopsy collection of visceral adipose tissue (omental, retroperitoneal and mesenteric) 
and subcutaneous adipose tissue (nuchal ligament and tailhead).  A portion of tissue from each 
site (~200 mg) was photolabeled and the remaining sample was flash frozen in liquid nitrogen. 
Please note that all procedures were approved by the Ohio State University Institutional Animal 
Care and Use Committee.  All tissues collected were stored at -80°C until the time of analysis. 
 
IN VITRO, WESTERN BLOTTING: 
Total GLUT (-4 & -12) and AS160 (total and phosphorylated) protein expression were measured 
in tissue homogenates by use of electrophoresis and subsequent western blotting. For analysis of 
GLUT-4 and GLUT-12, plasma membrane-enriched fractions were obtained from adipose tissue 
and skeletal muscle of insulin-sensitive and insulin-resistant horses, as previously described12.  
Frozen tissue fractions were homogenized in homogenizing buffer (210 mM Sucrose, 40 mM 
NaCl, 2 mM EGTA, 30 mM Hepes, and 0.35 mg/ml PMSF, pH 7.4) using a polytron homgenizer 
(Biospec Products, Inc).  The homogenate was then mixed with 58.3 mM sodium metaperiodate 
and 1.17 M KCl. Plasma membrane-enriched fractions were then recovered from muscle and fat 
by centrifugation (100,000 g, 70.1 Ti rotor, ultracentrifuge, Beckman Coulter).  The pellets were 
resuspended in 10 mM Tris, 1 mM EDTA (pH 7.4), and then 16% SDS was added.  Samples 
were then centrifuged again.   
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Total lysates for analysis of AS-160 and phosphorylated-AS160 were also obtained from insulin-
sensitive and insulin-resistant horses.  Frozen tissue fractions were homogenized in 
homogenizing buffer [50 mM Tris-HCl at pH 7.4, 50 mM sodium pyrophosphate, 5 mM sodium 
orthovanadate, 50 mM sodium fluoride, 5 mM EDTA, 1% Triton X-100, 10 uL/mL buffer 
protease inhibitor cocktail, and 10 uL/mL buffer phosphatase inhibitor cocktail (for 
phosphorylated-AS160 only) using a polytron homogenizer.  Total lysates were recovered from 
fat by centrifugation (10,000g, 70.1 Ti Rotor, ultracentrifuge, Beckman Coulter) and by 
extraction of the supernatant. 
Protein concentrations of the supernatant were determined spectrophotometrically (Microplate 
reader, Fluostar Optima, BMG Labtech) using a BCA Protein Assay Kit in conjunction with a 
BSA standard (Pierce, Rockford, IL).  Adipose tissue fractions were then analyzed for GLUT-4, 
GLUT-12, and AS160 by electrophoresis and subsequent western blotting.  Samples were diluted 
in 1:2 laemmli sample buffer (Bio-Rad, Hercules, CA) and separated by sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE) on a 12% resolving gel for GLUT-4 and 
GLUT-12 and a 7% resolving gel for AS160.  The protein was then transferred 
electrophoretically to a PVDF membrane (Millipore, Bedford, MA) using a semi-dry blotting 
technique.  The membranes were then blocked in a non-fat dry milk solution of 10% for GLUT-
4, 5% for GLUT-12, and 0.5% for AS160 (Bio-Rad, Hercules, CA) in 0.1% phosphatase-
buffered saline tween (TPBS).  After blocking, the membrane was incubated with a polyclonal 
antibody directed against the last 12 COOH-terminal amino acids of either GLUT-4, GLUT-12, 
or AS160.  After several washes in 0.1% TPBS and one wash in phosphatase-buffered saline 
(PBS), the membrane was incubated for 1 hr with an anti-rabbit horseradish peroxidase (GE 
Healthcare, Buckinghamshire, UK).  Quantitative determination of GLUT-4, GLUT-12, and 
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AS160 was performed by autoradiography after revealing the antibody-bound transporter protein 
enhanced by chemiluminescence reaction (Kirkegaard and Perry Laboratories, Maryland, USA) 
according to the manufacturer recommendations.  The density of the bands on scanned 
autoradiograph was quantified using a computerized densitometry program (MediaCybernetics, 
Silver Spring, MD).  Kaleidoscope prestained standards (Bio-Rad, Hercules, CA) were used as a 
molecular weight marker for each gel to confirm the molecular weight of the labeled bands.  For 
control samples, a rat left-ventricle from a previous study within this lab was used as an internal 
control in GLUT-4 and GLUT-12 studies, and a pig right atrium from a previous study in this lab 
was used as an internal control for the AS160 studies.                                   
Calsequestrin (CASQ2) was used as a loading control.  Previously analyzed membranes were 
stripped in western blot stripping buffer (Pierce, Rockford, IL).  Complete removal of the GLUT 
primary and AS160 primary, as well as secondary, was confirmed according to manufacturer 
recommendations.  Immunoblotting was then performed as described above, using a polyclonal 
antibody aimed at CASQ2 (Fisher Scienctific, Hanover Park, IL).   
 
IN VITRO, PHOTOLABELED TECHNIQUE: 
GLUT-4 translocation to the cell surface, the rate-limiting step in glucose utilization, was 
measured by a cell-surface biotinylation assay, using a photolabeled cell-impermeant compound 
in adipose tissue.  Please note all processes related to the biotinylation assay were performed by 
the post doctorate fellow in our lab, Dr. Amanda Waller 
.  
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RESULTS: 
IN VIVO: 
There were no significant differences in body weight, body condition score, neck circumference, 
girth, or ultrasonographic retroperitoneal fat thickness between groups (Table 1). There were 
also no differences in baseline blood glucose or plasma insulin concentrations (Table 1). Insulin 
sensitivity was significantly lower in insulin-resistant versus insulin-sensitive horses (P=0.014, 
Table 1).  The peripheral insulin resistance was compensated by a tendency for increased insulin 
response (AIRg), such that neither glucose effectiveness (Sg) nor secretory function (DI) were 
significantly lowered in insulin-resistant compared to insulin-sensitive horses (Table 1), thus 
validating the large animal model of naturally occurring insulin resistance. 
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Table 1. Baseline parameters in insulin sensitive and insulin resistant horses. 
 
 
 
 
 
 
 
 
 
 
 
 
SI: insulin sensitivity, AIRg: acute insulin response to glucose, Sg: glucose effectiveness, DI: disposition index [=SI 
X AIRg].* denotes significant difference between groups (P<0.05). n=5/group. 
 Insulin Sensitive Insulin Resistant 
Body weight (kg) 534.4 ± 28.8 510.2 ± 11.5 
Body Condition Score 6.5 ± 0.7 7.0 ± 0.2 
Basal [Insulin] (mIU L-1) 16.4 ± 5.8 18.7 ± 4.4 
Basal [Glucose] (mg dL-1) 100.2 ± 4.75 101.3 ± 3.76 
SI (L min-1 mU-1) 2.53 ± 0.60 0.62 ± 0.11 * 
AIRg (mU L-1 min-1) 405.6 ± 80.0 983.6 ± 256.2 
DI  874.0 ± 221.6 593.4 ± 83.9 
Sg (min-1) 1.67 ± 0.12 1.93 ± 0.28 
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TOTAL GLUT CONTENT IN ADIPOSE TISSUE OF INSULIN-SENSITIVE HORSES: 
Total GLUT-4 and GLUT-12 protein content were measured in plasma membrane enriched 
fractions across the various adipose tissue depots (Fig. 1).  Differential expression was noted 
across the various adipose tissue sites, with total GLUT-4 protein content being elevated in 
visceral (mesenteric and omental) adipose tissue compared to the corresponding subcutaneous 
adipose tissue sites (Fig. 1).  Similarly, total GLUT-12 protein content was significantly greater 
in visceral adipose tissue (mesenteric, with a tendency in omental) compared to subcutaneous 
adipose tissue depots in the insulin-sensitive horses (Fig. 1). 
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Fig. 1 Differential protein expression of total GLUT-4 (white bars) and GLUT-12 (black bars) across various 
visceral and subcutaneous adipose tissues.  Top panel: Representative Western blot of GLUT from a plasma 
membrane-enriched preparation of adipose tissue.  Calsequestrin (CASQ) protein content was used as a loading 
control.  Bottom panel: Mean±SE total content of GLUT protein in skeletal muscle (SM) vs. visceral [omental 
(OM), retroperitoneal (RP), and mesenteric (MES)] and subcutaneous [tailhead (TH) and nuchal (NL)] adipose 
tissue depots (n=5/group).  Relative units were expressed in relation to the skeletal muscle of insulin-sensitive 
subjects. *: Significantly greater than the skeletal muscle control group †: Significantly greater than all subcutaneous 
sites within the same insulin-sensitive group, P=0.05.  Please note that there is a tendency for GLUT-12 content to 
be higher in the omental site compared to other sites during the insulin-sensitive state.     
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TOTAL GLUT CONTENT IN IS vs. IR HORSES: 
A comparison of total glucose transporter content in insulin-sensitive versus insulin-resistant 
horses showed 44% lower total GLUT-4 content in omental adipose tissue of the insulin-resistant 
group compared to the control insulin-sensitive group (P=0.027, Fig 2A).  In contrast, there were 
no significant differences in total GLUT-4 protein content between insulin-sensitive and insulin-
resistant horses for all other adipose tissue sites sampled.  Similarly, no differences were 
observed in total GLUT-12 content (Fig. 2B) for any of the adipose tissue sites sampled between 
groups. 
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Fig. 2 Compensated insulin resistance (IR) induces decreases in omental total GLUT-4 protein content.  Top panel: 
Representative Western blot of GLUT from a plasma membrane-enriched preparation of subcutaneous and visceral 
adipose tissues.  Calsequestrin (CASQ) protein content was used as a loading control.  Bottom panel: Mean±SE of 
total GLUT-4 (A) and GLUT-12 (B) protein content in various visceral and subcutaneous adipose tissue depots 
during insulin-sensitive (IS) and insulin-resistant (IR) states (n=5 per group).  Relative units were expressed in 
relation to IS horses for each specific depot; ‡: P=0.05 vs. IS group.  Please refer to Fig. 1 for legends. 
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GLUT TRANSLOCATION IN IS vs. IR. HORSES: 
Active cell-surface GLUT content was quantified in photolabeled subcutaneous and visceral 
adipose tissue in order to determine whether insulin resistance corresponded to decreased total 
GLUT content and/or decreased GLUT translocation.  An overall group effect was noted, with 
significantly lower (P=0.033) active cell surface GLUT-4 content in adipose tissue of insulin-
resistant compared to insulin-sensitive subjects (by 63% and 70% in visceral and subcutaneous 
adipose sites, respectively, Fig. 3), suggesting that insulin resistance decreased GLUT-4 
translocation to the cell-surface in the adipose tissue.  In contrast, there was no difference in cell-
surface GLUT-12 content between groups for either subcutaneous or visceral sites (P=0.454, 
Fig. 4). 
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Fig. 3 Insulin resistance decreases active cell-surface GLUT-4 in photolabaled adipose tissue.  (A): Representative 
Western blot of cell-surface GLUT-4 during insulin-sensitive (IS) and insulin-resistant (IR) states.  L: labeled 
fraction; UL: unlabeled fraction; TL: total lysate.  (B) Mean±SE of labeled cell-surface content of active GLUT-4 in 
subcutaneous (SC; tailhead) and visceral (Vis; omental and mesenteric) adipose sites during insulin-sensitive (IS) 
and insulin-resistant (IR) states (n=2-4/group).  Relative units expressed in relation to an internal positive control; *: 
P=0.05 vs. IS group. 
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Fig. 4 Insulin resistance does not alter active cell-surface GLUT-12 in photolabeled adipose tissue. (A): 
Representative Western blot of cell-surface GLUT-12 in insulin-sensitive (IS) and insulin-resistant states.  (B): 
Mean±SE of labeled cell-surface content of active GLUT-12 in subcutaneous and visceral adipose sites (n=2-
4/group).  Relateive units expressed in relation to an internal positive control.  Please refer to Fig. 3 for legends. 
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AS160 ACTIVATION IN IS vs. IR HORSES: 
In order to characterize potential molecular mechanisms underlying the alterations in GLUT-4 
trafficking, AS160 was quantified in subcutaneous and visceral adipose tissue, and no 
differences in total AS160 (Fig. 5A, P=0.799) or phosphorylated-AS160 (Fig. 5B, P=0.896) 
were found between groups for each site. 
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Fig. 5 The decrease in active GLUT-4 content in omental tissue occurs despite normal activation of AS160 during 
the insulin-resistant state.  Total Protein content of (A) AS160 and (B) phosphorylated AS160 in adipose tissue 
during insulin-sensitive (IS) and insulin-resistant (IR) states (n=5 per group).  Top panel: Representative Western 
blot of AS160 in adipose total tissue.  Bottom panel: Mean±SE of protein expression of total AS160 (A) and 
phosphorylated AS160 (B) in subcutaneous (SC; tailhead) and visceral (VIS; omental and mesenteric) adipose sites. 
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DISCUSSION: 
Our data demonstrated that: 1) healthy insulin-sensitive horses exhibit differential GLUT protein 
expression across various visceral and subcutaneous adipose sites, with greater GLUT-4 and 
GLUT-12 expression noted in visceral (mesenteric and omental) adipose tissue; 2) insulin 
resistance decreases total omental GLUT-4, but not GLUT-12, protein content; 3) insulin 
resistance decreases GLUT-4, but not GLUT-12, translocation to the cell surface in photolabeled 
visceral and subcutaneous adipose tissue; 4) these changes occur independently of alterations in 
AS160 activity; 5) this large animal model of naturally occurring insulin resistance provided 
some novel insights into the molecular mechanisms involved in the pathogenesis of IR and may 
provide some novel therapeutic targets for the prediabetic and diabetic population. 
 
TOTAL GLUT CONTENT IN ADIPOSE TISSUE OF INSULIN-SENSITIVE HORSES: 
Differential GLUT protein expression was found across various visceral and subcutaneous 
adipose tissue depots in the healthy, insulin-sensitive subjects.  Total GLUT-4 and GLUT-12 
content were noted to be higher in visceral (e.g. omental and mesenteric) adipose tissue when 
compared against their subcutaneous counterparts, consistent with previous studies showing that 
visceral adipose tissue likely plays a comparatively more substantial role in systemic glucose 
homeostasis5. 
 
GLUT-4 CHARACTERIZATION IN ADIPOSE TISSUE OF INSULIN-RESISTANT HORSES: 
GLUTs are required for the facilitated diffusion of glucose across the plasma membrane where 
glucose is oxidized by the cell in order to obtain high energy phosphates (i.e., ATP), which are 
required for cellular processes. GLUT-4 is predominantly expressed in insulin-sensitive tissues 
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(e.g., muscle and adipose tissue), and it is known to play a crucial role in whole-body glucose 
homeostasis.  In our study, we quantified total GLUT-4 content in the insulin-sensitive versus 
insulin-resistant horses within our sampled adipose tissues.  Further, we investigated the effects 
of insulin-resistance on the rate-limiting step of glucose uptake into insulin-sensitive tissues, 
GLUT-4 translocation to the cell-surface membrane.  Insulin resistance decreased total GLUT-4 
content in omental adipose tissue only, with no significant differences found in the other sampled 
adipose tissue sites.  Additionally, insulin resistance resulted in decreased active GLUT-4 
content at the cell surface in visceral (mesenteric and omental) and subcutaneous (tailhead) 
adipose tissue when compared to insulin-sensitive counterparts.  While the mechanisms involved 
in the pathogenesis of insulin resistance remain poorly understood, our data from a large animal 
model exhibiting the earliest stages of preclinal diabetes suggests that decreased total omental 
GLUT-4 protein content and/or decreased GLUT-4 translocation may be contributory or even 
primary factors in the creation of the insulin resistant (and eventually diabetic) phenotype. 
 
GLUT-12 CHARACTERIZATION IN ADIPOSE TISSUE OF INSULIN-RESISTANT HORSES: 
GLUT-12 is a more recently identified GLUT that, according to some studies, may serve as a 
second insulin-sensitive transporter protein6.  In conjunction with our GLUT-4 studies, we 
examined total GLUT-12 content in the insulin-sensitive versus the insulin-resistant horses 
within our sampled adipose sites.  We also examined active cell-surface GLUT-12 via the same 
photolabeling technique used to examine GLUT-4.  Insulin resistance was not associated with 
any significant alterations in total GLUT-12 or active cell-surface protein content in any of our 
surveyed adipose tissue depots, suggesting that GLUT-12 is not a pathogenic factor during 
insulin resistance.   
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AS160 ACTIVITY IN ADIPOSE TISSUE OF INSULIN-RESISTANT HORSES: 
AS160 is a recently discovered signaling protein in the calcium/contraction- and insulin-
signaling pathways that regulates GLUT-4 translocation.  It is currently the most distally known 
signaling protein in these pathways.  In direct relation to the dysregulation of GLUT-4 
translocation in the sampled adipose tissues, AS160 was proposed as a potential molecular 
mechanism for this decreased GLUT-4 activation.  In theory, decreased phosphorylation (and 
thus activation) of AS160 could have been responsible for the decreased GLUT-4 activation, as 
AS160 activation is known to be associated with GLUT-4 translocation to the cell-surface.  Our 
results, however, indicated no changes in the protein content of either total or phosphorylated 
(active) AS160 between insulin-sensitive and insulin-resistant horses in the adipose tissues 
sampled, denoting that the changes in total omental GLUT-4 content and adipose GLUT-4 
translocation were occurring independently of any changes in AS160 activity. 
 
NOVEL, LARGE ANIMAL MODEL OF NATURALLY OCCURRING INSULIN-RESISTANCE: 
Our equine subjects served as excellent large animal models of insulin resistance.  This is a novel 
example of naturally occurring insulin resistance versus past models which have relied upon 
artificially induced insulin resistance through transgenicity or a combination of diet and 
pharmaceutical compounds.  Additionally, the equine animal model allowed for easier tissue 
collection, with much larger tissues to biopsy, and these animals provided a more translatable 
research model, as horses thermoregulate (i.e. sweating and shivering) more in accordance with 
humans, whereas rodents typically rely on brown adipose tissue lipolysis.  Furthermore, our 
equine model only exhibits the physiological characteristics of the prediabetic or insulin resistant 
state, whereas rodent models typically display early onset hyperglycemia, an inappropriate 
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physiological attribute for characterizing insulin resistance.  With all this in mind, this equine 
model of naturally occurring insulin resistance provided novel insights into the molecular 
mechanisms involved in the pathogenesis of insulin resistance and may yet provide some novel 
therapeutic targets for prediabetic or diabetic patients. 
 
CONCLUSION: 
In summary, naturally occurring compensated insulin resistance in this large animal model is 
characterized by selective impairment of the glucose transport pathways, namely that active cell-
surface GLUT-4 content was lower in adipose tissue (visceral and subcutaneous) depots of the 
insulin-resistant compared to the insulin-sensitive group, while total GLUT-4 content was only 
noted to be reduced in omental adipose tissue.  In addition, GLUT-12, one of the most recently 
discovered GLUT isoforms, does not appear to be a pathogenic factor in our model of the early 
stages of insulin resistance, since neither its total nor active content were affected in any of the 
sampled adipose depots in the insulin-resistant state.  It is concluded that adipose tissue GLUT-4, 
but not GLUT-12, particularly in the omental site, contributes to the pathogenesis of naturally 
occurring compensated insulin resistance. 
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